Fairvalue-Calculator Fairvalue-Calculator
EN DE

Milestone Pharmaceuticals Inc (MIST) Fair Value & Analysis

Healthcare · US · Market cap $162M

Price$1.30
Fair Value$1.51
Upside+16.2%
Quality95/100
Evidence: Low Range $1.13 – $1.89

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Milestone Pharmaceuticals Inc (MIST) currently trades at $1.30, while our model-based Fair Value estimate is $1.51 — implying the stock looks roughly 16.2% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. The company is also developing etripamil for the indication of atrial fibrillation with rapid ventricular rate (AFib-RVR). It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montreal, Canada.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +1% Alnylam Pharmaceuticals, Inc (ALNY) -82%

Frequently asked questions

Is Milestone Pharmaceuticals Inc (MIST) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $1.51 versus a price of $1.30 — about +16% (undervalued). Model-based estimate, not financial advice.
What is the fair value of MIST?
Our 21-model fair value for Milestone Pharmaceuticals Inc is $1.51 (as of Jun 24, 2026), built from audited fundamentals. The current price is $1.30.
What is the quality score of MIST?
Milestone Pharmaceuticals Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.